Press Release
Full Year 2006 Results Date Notification - 23 February 2007
14 Feb 2007 - Basingstoke, UK and Philadelphia, US – 14 February 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) will announce full year 2006 earnings on Friday 23 February 2007.
Results press release will be issued at: 12:00 GMT / 07:00 ET
Investor Meeting & conference call time: 14:00 GMT / 09:00 ET
Live analyst presentation and conference call:
Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the investor and analyst meeting and live conference call at 14:00 GMT/9:00 ET. The venue for the meeting will be at the offices of Financial Dynamics, Holborn Gate, 26 Southampton Buildings, London WC2A 1PB
Please RSVP claire.rowell@fd.com for the live presentation.
Live conference call and Webcast:
The details of the live conference call and Webcast are as follows:
US Toll Free Dial In Number: 1 866 793 4279
UK Toll Free Dial In Number: 0800 358 2705
Standard International Dial In Number: +44 (0) 20 8609 0205
Conference ID / Pin Code: 292846#
Audio webcast: www.shire.com, in the Investor Relations/Events section
Please RSVP ssalah@shire.com for the conference call
Latest Press Releases
- Shire delivers strong quarter driven by 3m of new product sales
- Jerini receives european commission approval for FIRAZYR® (Icatibant) in HAE treatment
- Shire to add new orphan drug to its HGT portfolio - EU launch imminnent
- Graham Hetherington appointed Chief Financial Officer and Board Director at Shire
- First and Only Treatment for Hunter Syndrome Now Approved in 40 Countries Worldwide
- Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans
- Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair
- Publication of Supplementary Prospectus
- Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy
- FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
Spread your message to an audience that counts, with options available for our website, email bulletins and publications including The House Magazine.
